NovaBay Pharmaceuticals Reports Board and Compensation Changes

TL;DR

NovaBay shuffled its board and exec pay. Keep an eye on strategy shifts.

AI Summary

NovaBay Pharmaceuticals, Inc. announced on October 9, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. This is a routine filing to update the SEC on corporate governance and compensation matters.

Why It Matters

Changes in a company's board of directors and executive compensation can signal shifts in strategy or operational focus, impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which are standard disclosures and do not inherently indicate significant operational or financial risk.

Key Players & Entities

• NovaBay Pharmaceuticals, Inc. (company) — Registrant
• October 9, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-33678 (file_number) — SEC File Number
• 68-0454536 (ein) — IRS Employer Identification No.
• 2000 Powell Street, Suite 1150, Emeryville, CA 94608 (address) — Principal executive offices
• (510) 899-8800 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share NBY NYSE American Indic

Filing Documents

• novabay_8k.htm (8-K) — 25KB
• 0001829126-25-007992.txt ( ) — 186KB
• nby-20251009.xsd (EX-101.SCH) — 3KB
• nby-20251009_lab.xml (EX-101.LAB) — 33KB
• nby-20251009_pre.xml (EX-101.PRE) — 22KB
• novabay_8k_htm.xml (XML) — 4KB

02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 9, 2025, in connection with his entry into the Securities Purchase Agreement (as defined in Item 8.01 below), David Lazar tendered his resignation as Chief Executive Officer and a director of NovaBay Pharmaceuticals, Inc. (the "Company"), to be effective upon the release of the Escrow Funds from the Escrow Agent (each as defined in the Securities Purchase Agreement) to Mr. Lazar pursuant to the Securities Purchase Agreement.

01 Other Events

Item 8.01 Other Events. As previously disclosed in the Company's definitive proxy statement relating to its 2025 Annual Meeting of stockholders (the "Proxy Statement"), the Securities Purchase Agreement dated as of August 19, 2025 between the Company and Mr. Lazar provided for the ability of Mr. Lazar to assign, transfer and/or sell his shares of Series D Preferred Stock, Series E Preferred Stock, the Conversion Shares (each as defined in the Proxy Statement) and/or his right acquire such securities. On October 9, 2025, David Lazar (the "Seller") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with R01 Fund LP ("R01") and Framework Ventures IV L.P. ("Framework" and, together with R01, the "Purchasers") to effect such transfer. Pursuant to the Securities Purchase Agreement, the Seller agreed to assign to the Purchasers all of the Seller's right, title and interest in (i) 441,325 shares of Series D Non-Voting Convertible Preferred Stock, $0.01 par value per share, of the Company (the "Series D Preferred Stock") and (ii) the rights and obligations to purchase 268,750 shares of Series E Non-Voting Convertible Preferred Stock, $0.01 par value per share of the Company (the "Series E Rights" and, together with the Series D Preferred Stock, the "Transferred Stock" and the transactions contemplated by the Securities Purchase Agreement, the "Purchase"), each of which were purchased from the Company by the Seller pursuant to that certain Securities Purchase Agreement, dated as of August 19, 2025, by and between the Seller and the Company (the "August Agreement"). The Purchase is subject to, among certain customary closing conditions, the approval by the stockholders of the Company of the proposals 5 and 9, each as set forth in the Proxy Statement, at the Company's 2025 Annual Meeting of stockholders to be held on October 16, 2025. In connection with the Securities Purchase Agreement, the Company agreed to perform its covenants and obligatio

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: October 9, 2025 NovaBay Pharmaceuticals, Inc. By: /s/ Tommy Law Name: Tommy Law Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR